207 related articles for article (PubMed ID: 38397136)
21. Clinical utility of peripheral blood laboratory testing in the diagnostic workup of prurigo nodularis: A multicenter cohort study.
Cornman HL; Deng J; Kambala A; Parthasarathy V; Reddy SV; Kwatra SG
JAAD Int; 2023 Dec; 13():74-82. PubMed ID: 37711338
[TBL] [Abstract][Full Text] [Related]
22. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis.
Deng J; Parthasarathy V; Marani M; Bordeaux Z; Lee K; Trinh C; Cornman HL; Kambala A; Pritchard T; Chen S; Sutaria N; Oladipo OO; Kwatra MM; Alphonse MP; Kwatra SG
Front Med (Lausanne); 2022; 9():1022889. PubMed ID: 36619628
[TBL] [Abstract][Full Text] [Related]
23. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
[TBL] [Abstract][Full Text] [Related]
24. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis.
Haas S; Capellino S; Phan NQ; Böhm M; Luger TA; Straub RH; Ständer S
J Dermatol Sci; 2010 Jun; 58(3):193-7. PubMed ID: 20417061
[TBL] [Abstract][Full Text] [Related]
25. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
[TBL] [Abstract][Full Text] [Related]
26. Skin Microbiome in Prurigo Nodularis.
Tutka K; Żychowska M; Żaczek A; Maternia-Dudzik K; Pawełczyk J; Strapagiel D; Lach J; Reich A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108838
[TBL] [Abstract][Full Text] [Related]
27. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
28. Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study.
Taghaddos D; Savinova I; Abu-Hilal M
J Cutan Med Surg; 2024; 28(2):141-145. PubMed ID: 38281092
[TBL] [Abstract][Full Text] [Related]
29. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis.
Parthasarathy V; Cravero K; Xu L; Deng J; Sun Z; Engle SM; Sims JT; Okragly AJ; Kwatra SG
J Am Acad Dermatol; 2023 May; 88(5):1101-1109. PubMed ID: 36806647
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
32. REMOVED: Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.
Chu L; Wang L; Wu Y; Yang H; Wang W; Lu Q; Deng H
Actas Dermosifiliogr; 2022 Mar; 113(3):T244-T253. PubMed ID: 35331446
[TBL] [Abstract][Full Text] [Related]
33. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.
Murota H; Arima K; Yoshida T; Fujita H
J Dermatol; 2024 Feb; 51(2):223-233. PubMed ID: 38066728
[TBL] [Abstract][Full Text] [Related]
34. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.
Belzberg M; Alphonse MP; Brown I; Williams KA; Khanna R; Ho B; Wongvibulsin S; Pritchard T; Roh YS; Sutaria N; Choi J; Jedrych J; Johnston AD; Sarkar K; Vasavda C; Meixiong J; Dillen C; Bondesgaard K; Paolini JF; Chen W; Corcoran D; Devos N; Kwatra MM; Chien AL; Archer NK; Garza LA; Dong X; Kang S; Kwatra SG
J Invest Dermatol; 2021 Sep; 141(9):2208-2218.e14. PubMed ID: 33771530
[TBL] [Abstract][Full Text] [Related]
35. Serotonin and interleukin-6: Association with pruritus severity, sleep quality and depression severity in Prurigo Nodularis.
Konda D; Chandrashekar L; Rajappa M; Kattimani S; Thappa DM; Ananthanarayanan PH
Asian J Psychiatr; 2015 Oct; 17():24-8. PubMed ID: 26277226
[TBL] [Abstract][Full Text] [Related]
36. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
37. A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications.
Agrawal D; Sardana K; Mathachan SR; Bhardwaj M; Ahuja A; Jain S
J Cosmet Dermatol; 2022 Sep; 21(9):4009-4015. PubMed ID: 34965028
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
40. Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study.
Olbrich H; Kridin K; Hernández G; Zirpel H; Sadik CD; Terheyden P; Thaçi D; Ludwig RJ; Boch K
EBioMedicine; 2024 May; 103():105123. PubMed ID: 38631094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
